Jóhannesson G, et al. - Researchers conducted this randomized prospective single masked clinical trial to compare nonmitomycin C (MMC) trabeculectomy and 1.5% dexamethasone nanoparticle (DexNP) eye drops postoperatively with trabeculectomy with MMC and Maxidex® eye drops postoperatively. The sample consisted of 20 individuals with primary open-angle glaucoma undergoing primary trabeculectomy. The study group comprised of 10 patients without MMC intraoperatively and postoperative DexNP eye drops. The control group comprised of 10 patients treated with MMC intraoperatively and postoperative Maxidex®. According to results, both groups demonstrated similar postoperative course and IOP reduction. No statistically significant differences were found between the groups in absolute or relative success rates, the number of medications or reoperations between the groups at any time-point. Findings suggested that DexNP eye drops are an effective postoperative after-trabeculectomy treatment. DexNP's potent anti-inflammatory and antifibrotic effect in glaucoma surgery may offer an alternative to mitomycin C.